or
Bookmark and Share
Aspirin tablet
   
Document Number
US Patent 4555399
Issued Date
November 26, 1985
Link
Inventors
Map
Abstract
A tablet, which readily disintegrates in gastric fluid to give aspirin crystals coated with a polymeric film preventing the aspirin crystals from contacting the stomach wall but not preventing access of gastric fluid to the aspirin contained within the polymer film, which consists of a plurality of aspirin crystals 20-60 mesh in size coated with about 3-10% by weight of a polymeric mixture comprising from about 1.5 to about 15 parts by weight ethylcellulose and about one part by weight hydroxypropylcellulose; a compression aid; a disintegrant; and a tableting aid.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
7
Comments:
no comments yet
Owner
Published
November 26, 1985
Application Number
06/587,533
Filed
March 8, 1984
US Classification
424/465   424/497 514/165
Int'l Classification
A61K   31/60   (20060101)   A61K   9/20   (20060101)   A61K   9/50   (20060101)  
Examiner
Attorney/Law Firm
Parent Case
This application is a continuation-in-part of my application Ser. No. 553,256, filed Nov. 18, 1983, now abandoned.
USPTO Field of Search
424/16   424/19   424/20   424/21   424/22   424/35   424/80   424/230  
Related Patents
4639370 - Pharmaceutical composition - Owned by Farmitalia Carlo Erba S.p.A. (Milan,IT)

A water-swellable, water-insoluble polymer is loaded with a biologically active substance or substance convertible into a biologically active substance in vivo by preparing and grinding a mixture of a said substance with a water-swellable, water-insoluble polymer in a weight ratio of the said substance:polymer of from 1:0.1 to 1:100. The thus-loaded polymer is useful as a pharmaceutical composition.

5009897 - Pharmaceutical granules and tablets made therefrom - Owned by Abbott Laboratories (Abbott Park, IL)

A pharmaceutical granule comprising a core of active pharmaceutical agent and a coating of a polymer/microcrystalline cellulose is provided. These granules permit superior tableting of pharmaceutical agents whose physical properties in granule form render them unsuitable for conventional tableting.

4837031 - Compositions containing ibuprofen - Owned by Mallinckrodt, Inc. (St. Louis, MO)

A granular composition containing 2-(4-isobutylphenyl)propionic acid (ibuprofen) as an active anti-inflammatory pharmaceutical ingredient as a major component, together with carboxymethylcellulose, a lubricant and water as minor components, is disclosed. Particles of ibuprofen and carboxymethylcellulose are both fluidized and coated with an aqueous disperson of a starch binder. After being dried to a moisture level of about 1-5% and blended with a lubricant and additional carboxymethylcellulose, the resulting granules can be directly molded into a pharmaceutically acceptable tablet having high hardness, short disintegration time and fast dissolution rate.

5064656 - Uncoated pharmaceutical reaction tablet - Owned by Dr. Gergely & Co. (CH)

An uncoated compressed tablet which is used for the preparation of an orally applicable aqueous suspension or solution of a pharmaceutically active substance contains a mixture of the pharmaceutically active substance, a swelling disintegrant and an effervescent system. The weight ratio of the disintegrant to the effervescent system is from 0.1:1 to 4:1.

4863743 - Controlled release potassium chloride - Owned by Key Pharmaceuticals, Inc. (Kenilworth, NJ)

A controlled release potassium chloride tablet is disclosed which is comprised of potassium chloride crystals having a mesh size of about 30 to about 50 mesh which are coated with a coating material comprised of ethylcellulose and hydroxypropylcellulose. The coated crystals form micro pellets which then can be compressed into tablets. The tablets disintegrate rapidly in an aqueous environment thus assuring a more uniform dissolution of the active component as compared with other types of controlled release potassium chloride dosage formulations. The distribution of the potassium chloride micro pellets over a wide surface area in the gastrointestinal mucosa aids in reducing the risk of gastrointestinal lesions. The formation of the coated micro pellets which disperse quickly upon contact with aqueous environment allow for the repeated chronic oral administration of a relatively large dose of potassium chloride (20 mEq).

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us